Rhodiola rosea 'WS 1375'

Rhodiola rosea WS 1375 is a standardized extract of Rhodiola rosea root, concentrated in the bioactive rosavins and salidroside, which modulate the hypothalamic-pituitary-adrenal (HPA) axis and inhibit catechol-O-methyltransferase (COMT) to prolong stress-resilience signaling. It is clinically studied specifically for chronic fatigue and occupational burnout, distinguishing it from generic Rhodiola preparations.

Origin & History

Rhodiola rosea WS 1375 is a standardized extract derived from the roots and rhizomes of Rhodiola rosea, a perennial flowering plant that grows naturally in Arctic regions of Europe and Asia. The extract is standardized to contain a minimum of 3.0% rosavins and 1.0% salidroside in their naturally occurring 3:1 ratio, produced through proprietary extraction methods designed to preserve and concentrate the plant's bioactive compounds.

Historical & Cultural Context

Rhodiola rosea has a long history of use in traditional medicine to stimulate the nervous system, treat stress-induced fatigue, and address depression. The plant contains approximately 140 chemical compounds, with rosavins and salidroside serving as the primary bioactive markers.

Health Benefits

• Reduces chronic fatigue symptoms with statistically significant improvements (p<0.0001) across all fatigue domains after 8 weeks (moderate evidence from open-label trial)
• Improves burnout symptoms with measurable decreases in all Perceived Stress Questionnaire subscales over 12 weeks (preliminary evidence from exploratory trial)
• Enhances concentration and memory with significant improvements on CDC scales for cognitive function (preliminary evidence from open-label study)
• Alleviates life-stress symptoms with clinically relevant improvements appearing as early as 3 days (preliminary evidence from multicenter trial)
• Supports cellular energy production by increasing bioenergetics and scavenging reactive oxygen species in stress models (preliminary evidence from in-vitro studies)

How It Works

WS 1375's primary bioactives—rosavins (rosavin, rosarin, rosin) and salidroside—inhibit COMT, slowing the degradation of dopamine, norepinephrine, and serotonin in stress-response pathways, thereby extending catecholamine availability. Salidroside additionally activates AMPK signaling and upregulates heat shock proteins (Hsp70, Hsp90), reducing cellular stress markers and supporting mitochondrial energy production. These combined actions buffer cortisol-driven HPA axis dysregulation without directly suppressing cortisol synthesis.

Scientific Research

Three open-label clinical trials have investigated WS 1375 for fatigue and stress-related symptoms, enrolling 101, 118, and 100 participants respectively over 4-12 week periods. All studies showed statistically significant improvements in fatigue measures, with the chronic fatigue study demonstrating p<0.0001 across all MFI-20 subscales. No PMIDs were provided in the research dossier.

Clinical Summary

An open-label trial (n=100) using WS 1375 at 400 mg/day over 8 weeks demonstrated statistically significant improvements across all measured fatigue domains (p<0.0001), including concentration, motivation, and mental performance, using validated fatigue scales. A separate 12-week observational study in occupational burnout patients showed measurable decreases across all subscales of the Perceived Stress Questionnaire (PSQ). Evidence quality is moderate to preliminary: open-label and observational designs limit causal conclusions due to absence of placebo controls and blinding. Larger randomized controlled trials are needed to confirm effect sizes and establish optimal dosing ranges for WS 1375 specifically.

Nutritional Profile

Rhodiola rosea 'WS 1375' is a standardized proprietary dry extract of Rhodiola rosea root, not a conventional food ingredient, so macronutrient and micronutrient framing is largely inapplicable; its profile is defined by its bioactive phytochemical fingerprint. The extract is standardized to contain rosavins (rosavin, rosarin, rosin) at approximately 3% total content and salidroside (p-tyrosol glucoside) at approximately 1% — a 3:1 rosavin-to-salidroside ratio reflecting the natural root composition and used as a quality marker. Typical clinical doses of WS 1375 are 200–400 mg/day of the dry extract. Key bioactive compound classes include: (1) Phenylpropanoids — rosavins (~3% standardized), the glycosylated cinnamyl alcohol derivatives considered primary marker compounds; (2) Phenylethanoids — salidroside (~1% standardized), also known as rhodioloside, a tyrosine-derived glucoside with well-documented adaptogenic and neuroprotective activity; its aglycone p-tyrosol is also present in smaller amounts and contributes to bioactivity; (3) Flavonoids — including rodiolin, rodionin, rodiosin, acetylrodalgin, and tricin, present at trace-to-low percentages; (4) Monoterpene alcohols — geraniol and myrtenol detected in volatile fractions; (5) Organic acids — gallic acid, chlorogenic acid, and hydroxycinnamic acid derivatives present at low milligram-per-gram levels; (6) Proanthocyanidins — oligomeric forms present in root matrix. Macronutrient content at clinical doses is negligible: at 200–400 mg extract per dose, carbohydrate, fat, and protein contributions are physiologically insignificant (estimated <0.1 g each per dose). Mineral content from the extract at these doses is trace-level and not a meaningful dietary source. Bioavailability notes: salidroside is hydrolyzed in the gastrointestinal tract to p-tyrosol, which is rapidly absorbed; peak plasma concentrations of p-tyrosol are reached within approximately 1 hour post-ingestion. Rosavins undergo partial hydrolysis and phase II conjugation (glucuronidation, sulfation) in intestinal and hepatic metabolism; absolute oral bioavailability data for intact rosavins in humans remains limited, though animal studies suggest moderate absorption with first-pass metabolism reducing systemic exposure. The extract matrix (dry powder from hydroethanolic extraction) does not contribute meaningful dietary fiber, fat-soluble vitamins, or minerals at therapeutic doses.

Preparation & Dosage

The clinically studied dosage for WS 1375 is 200 mg twice daily (400 mg total daily dose) for treatment durations of 4 to 12 weeks. Broader clinical effects have been observed with Rhodiola extract doses ranging from 340-680 mg daily for up to 42 days. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ashwagandha, L-theanine, Magnesium glycinate, B-complex vitamins, Cordyceps

Safety & Interactions

Rhodiola rosea WS 1375 is generally well tolerated; the most commonly reported adverse effects are mild and transient, including dizziness, dry mouth, and agitation, particularly at higher doses or when taken late in the day due to its mild stimulant properties. It may interact with CYP3A4-metabolized drugs, as salidroside and rosavins have demonstrated in vitro CYP enzyme modulation, warranting caution with immunosuppressants, anticoagulants, and antidepressants including SSRIs and MAOIs. Combining WS 1375 with stimulants or other adaptogens has not been rigorously studied and is not recommended without medical supervision. Safety data in pregnancy, lactation, and pediatric populations are insufficient, and use in these groups should be avoided.